Analyst Ranking
Top 43%
#2208 out of 5116 analysts
Average Return
+0.49%
Win Rate
52%14 out of 27
Risk vs Reward
Poor
Good

Michael Ryskin's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Singular Genomics Systems IncOMIC
+79.62%$103.20$21.03
2022-08-10 -
2023-08-09
Sell
Absci CorpABSI
+75.41%$12.89$3.17
2021-11-10 -
2022-11-09
Sell
Guardant Health IncGH
+51.78%$31.15$47.28
2024-07-18 -
2025-07-17
Strong Buy
Tempus Ai IncTEM
+48.55%$34.50$51.25
2024-07-09 -
2024-10-02
Strong Buy
Align Technology IncALGN
+37.47%$235.39$147.19
2024-12-13 -
2025-11-28
Sell

Michael Ryskin's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Revvity IncRVTY
1Strong Buy$99.00-5.18%Maintains
2 months ago
Tempus Ai IncTEM
6Hold$70.00-10.18%Maintains
5 months ago
Idexx Laboratories IncIDXX
3Hold$475.00-36.91%Maintains
7 months ago
Maravai Lifesciences Holdings IncMRVI
3Strong Buy$8.00+120.99%Maintains
9 months ago
Align Technology IncALGN
6Sell$206.00+39.96%Maintains
a year ago
Guardant Health IncGH
1Strong Buy$40.00N/AMaintains
a year ago
Alight IncALIT
1Strong Buy$9.50N/AMaintains
a year ago
Exscientia PLCEXAI
2Hold$9.00N/ADowngrades
2 years ago
Certara IncCERT
2Strong Buy$24.00N/AMaintains
2 years ago
Avantor IncAVTR
2Strong Buy$24.00N/AMaintains
2 years ago
Abcam PLCABCM
2Strong Buy$25.00N/AUpgrades
2 years ago
Zoetis IncZTS
6Strong Buy$180.00N/AMaintains
3 years ago
Singular Genomics Systems IncOMIC
3Sell$90.00N/ADowngrades
3 years ago
Recursion Pharmaceuticals IncRXRX
1HoldN/AN/ADowngrades
4 years ago
Schrodinger IncSDGR
2Hold$52.00N/ADowngrades
4 years ago
Absci CorpABSI
2Sell$10.00N/ADowngrades
4 years ago
Smiledirectclub IncSDCCQ
1Sell$7.00N/ADowngrades
6 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.